Ketoconazole

Treatment for Cushing's Syndrome

Typical Dosage: 200-1200 mg/day, divided doses

Effectiveness
60%
Safety Score
60%
Clinical Trials
4
Participants
2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
200-1200 mg/day, divided doses
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$1,500
Side Effect Mgmt:$500
Total Annual:$4,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$75,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$6,667
Cost per Remission
$6,667
Ketoconazole Outcomes

for Cushing's Syndrome

Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+60%
Remission Rate
+60%
Common Side Effects
Hepatotoxicity (elevated LFTs)
+15%
Nausea/Vomiting
+12%
Gynecomastia (men)
+12%
Hypogonadism
+8%

Sources:

researchgate.net
cushingsdiseasenews.com
oup.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
3 completed trials for Ketoconazole in Cushing's Syndrome

Treatment for Endogenous Cushing's Syndrome

NCT01838551COMPLETEDPHASE3
View Study
94 participants
INTERVENTIONAL
Los Angeles, United States +41 more
Started: Aug 1, 2014

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

NCT03277690COMPLETEDPHASE3
View Study
84 participants
INTERVENTIONAL
Los Angeles, United States +44 more
Started: Sep 26, 2017

Open-label Treatment in Cushing's Syndrome

NCT03621280COMPLETEDPHASE3
View Study
51 participants
INTERVENTIONAL
Fort Lauderdale, United States +29 more
Started: Jan 7, 2019